Mindera Corporationtoday announced a $12.6M Series A-2 capital raise. The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development. The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as continue development of the Mindera Dermal Intelligence™ Platform.
Mindera, generating clinically validated data to lower healthcare costs and improve patient care.
The Mindera platform uses a simple patch that extracts biomarkers from the skin in minutes, allowing for rapid and painless extraction of RNA. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. In the case of Mind.Px, this rich patient-specific data is then analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment.